AC 0100MA

Drug Profile

AC 0100MA

Alternative Names: AC 0100; AC 0100 Maleate; AC0010 MA

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator ACEA Biosciences
  • Developer ACEA Biosciences; Hangzhou ACEA Pharmaceutical Research
  • Class Antineoplastics; Heterocyclic compounds; Pyrimidines; Pyrroles
  • Mechanism of Action Apoptosis stimulants; Epidermal growth factor receptor antagonists; Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors; Ras protein inhibitors; Receptor protein-tyrosine kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I B cell lymphoma; Lung cancer

Most Recent Events

  • 28 Feb 2017 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (PO) (NCT03060850)
  • 10 Feb 2017 Hangzhou ACEA Pharmaceutical plans a phase I trial for B-cell lymphoma in China (NCT03060850)
  • 01 Nov 2016 Hangzhou ACEA Pharmaceutical initiates enrolment in a phase I trial for Non-small cell lung cancer (Late-stage disease, Recurrent, Second-line therapy or greater) in China (NCT03053219)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top